Pyruvate Kinase Deficiency — the most common glycolytic enzyme defect causing chronic hemolytic anemia, now with the first FDA-approved disease-modifying therapy (mitapivat, 2022) where the PKLR genotype determines treatment response.
Whole genome sequencing identifies all PKLR variants — determining whether mitapivat (Pyrukynd) will activate the patient's specific mutant pyruvate kinase enzyme or whether the variant produces a protein that cannot be pharmacologically rescued.
Hereditary Hemolytic Anemia — Glucose-6-Phosphate Isomerase Deficiency & Pyruvate Kinase Deficiency
Pyruvate kinase deficiency (PKD) is the most common glycolytic enzyme defect causing hereditary non-spherocytic hemolytic anemia (HNSHA), affecting approximately 1 in 20,000 people worldwide. It is caused by autosomal recessive pathogenic variants in PKLR (chromosome 1q22), encoding the liver/red cell isoform of pyruvate kinase. PK deficiency impairs glycolytic ATP production in mature red blood cells (which lack mitochondria and depend entirely on glycolysis for energy), causing chronic extravascular hemolysis with anemia, reticulocytosis, jaundice, splenomegaly, and gallstones.
Clinical severity varies widely — from fully compensated hemolysis (normal hemoglobin maintained by increased reticulocyte production) to transfusion-dependent severe anemia requiring regular red blood cell transfusions from infancy. Hydrops fetalis occurs in the most severe forms. Iron overload is a major long-term complication, developing in both transfusion-dependent and non-transfusion-dependent patients due to inappropriate intestinal iron absorption driven by chronic hemolysis and ineffective erythropoiesis. Splenectomy partially ameliorates the anemia but does not cure it and carries lifelong infection risk.
Mitapivat (Pyrukynd, Agios Pharmaceuticals) was FDA-approved in 2022 for hemolytic anemia in adults with PKD — the first disease-modifying therapy for any glycolytic enzymopathy. Mitapivat is an oral allosteric activator of pyruvate kinase that binds to and stabilizes the PK tetramer, increasing catalytic activity of the mutant enzyme. Treatment increases hemoglobin, reduces markers of hemolysis, and in transfusion-dependent patients can reduce or eliminate transfusion requirements. However, mitapivat responsiveness depends on the specific PKLR genotype — variants that produce no protein (null alleles) cannot be pharmacologically activated. Molecular PKLR genotyping is required for treatment planning.
Mitapivat can only activate PK variants that produce a structurally intact but functionally impaired enzyme. PKLR null variants (producing no protein) are non-responsive. Genotype determines whether the drug has a molecular target to work on.
PKD was previously managed only with splenectomy and transfusion support. Mitapivat changes this — but eligibility requires PKLR molecular genotyping to determine whether the specific variant can be pharmacologically rescued.
Mitapivat responsiveness depends on whether the PKLR variant produces an activatable enzyme — molecular genotyping makes this prediction
PKLR missense variants that produce a structurally intact but kinetically impaired pyruvate kinase enzyme are candidates for mitapivat activation — the drug stabilizes the PK tetramer and partially restores catalytic efficiency. In contrast, PKLR nonsense, frameshift, or splice variants that produce no stable protein cannot be pharmacologically rescued. Patients homozygous for null alleles are predicted non-responders, while patients compound heterozygous for a missense and null allele have intermediate response potential (one allele can be activated). This genotype-response relationship is clinically validated and directly determines treatment planning.
Iron overload in PKD develops even without transfusions — molecular diagnosis triggers proactive iron monitoring
Unlike thalassemia, where iron overload is primarily transfusion-driven, PKD patients develop iron overload from increased intestinal iron absorption mediated by suppressed hepcidin. Non-transfusion-dependent PKD patients can develop significant hepatic iron deposition and eventual cirrhosis without proactive monitoring and chelation therapy. Molecular PKD diagnosis — rather than a vague diagnosis of 'chronic hemolytic anemia' — ensures that the patient is entered into appropriate iron surveillance protocols (regular ferritin, liver MRI T2*) and receives chelation when indicated.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Hereditary Hemolytic Anemia — Glucose-6-Phosphate Isomerase Deficiency & Pyruvate Kinase Deficiency and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
